$8.84
3.60% day before yesterday
Nasdaq, Dec 27, 09:49 pm CET
ISIN
US1374041093
Symbol
CADL

Candel Therapeutics Inc Stock price

$8.87
+3.92 79.19% 1M
+2.98 50.59% 6M
+7.40 503.40% YTD
+7.48 538.13% 1Y
+1.06 13.57% 3Y
+1.87 26.71% 5Y
+1.87 26.71% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.30 3.27%
ISIN
US1374041093
Symbol
CADL
Sector
Industry

Key metrics

Market capitalization $394.50m
Enterprise Value $393.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-35.55m
Free Cash Flow (TTM) Free Cash Flow $-28.69m
Cash position $16.56m
EPS (TTM) EPS $-1.74
Short interest 8.06%
Show more

Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Candel Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Candel Therapeutics Inc:

Buy
100%

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.06 1.06
9% 9%
-
-1.06 -1.06
6% 6%
-
- Selling and Administrative Expenses 13 13
1% 1%
-
- Research and Development Expense 21 21
1% 1%
-
-34 -34
1% 1%
-
- Depreciation and Amortization 1.06 1.06
9% 9%
-
EBIT (Operating Income) EBIT -36 -36
1% 1%
-
Net Profit -52 -52
63% 63%
-

In millions USD.

Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Candel Therapeutics Inc Stock News

Positive
Proactive Investors
5 days ago
In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those focused on cancer immunotherapies, treatments for neurological conditions like multiple sclerosis and Alzheimer's, as well as novel approaches to metabolic diseases and chronic pain.
Positive
Proactive Investors
9 days ago
Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer.
Positive
Proactive Investors
12 days ago
Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common stock at $6 per share and pre-funded warrants for 3.3 million shares at $5.99 per warrant, allowing buyers to acquire shares at an exercise price of $0.01 each.
More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office United States
CEO Paul-Peter Tak
Employees 42
Founded 2002
Website www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today